Last reviewed · How we verify
Suicidal Behavior in Schizophrenia — Treatment Landscape & Competitive Intelligence
3 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Clozaril | CLOZAPINE | Jazz Pharmaceuticals | Atypical Antipsychotic [EPC] | D2, 5-HT2A | 1989-01-01 | |
| Fazaclo | Fazaclo | Manhattan Psychiatric Center | Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E | |||
| Clozaril | Clozaril | Dong Wha Pharmaceutical Co. Ltd. | Aldehyde oxidase, UDP-glucuronosyltransferase 1-4, 5-hydroxytryptamine receptor 1E |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Dong Wha Pharmaceutical Co. Ltd. · 1 drug in Suicidal Behavior in Schizophrenia
- Jazz Pharmaceuticals · 1 drug in Suicidal Behavior in Schizophrenia
- Manhattan Psychiatric Center · 1 drug in Suicidal Behavior in Schizophrenia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Suicidal Behavior in Schizophrenia:
- Suicidal Behavior in Schizophrenia treatment updates — RSS
- Suicidal Behavior in Schizophrenia treatment updates — Atom
- Suicidal Behavior in Schizophrenia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Suicidal Behavior in Schizophrenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/suicidal-behavior-in-schizophrenia. Accessed 2026-06-10.
Related
- Suicidal Behavior in Schizophrenia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing